Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of EP395 in COPD
NCT05572333Phase 2Completed
- Sponsor
- EpiEndo Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of glasmacinal in chronic obstructive pulmonary disease (COPD), sponsored by EpiEndo Pharmaceuticals. Started Nov 2022; status: completed.
02
Drugs
glasmacinal
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05572333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05572333.